Compare Citius Pharmaceuticals Inc (CTXR) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Lennar Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Lennar Corporation trades at $77.7 (market cap $18.10B). The key difference: Lennar Corporation is far larger — about 1312.5× Citius Pharmaceuticals Inc's market cap, and Lennar Corporation pays a 2.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Lennar Corporation for 67 Days on average.
| CTXR | LEN | |
|---|---|---|
Market Cap | $13.79M | $18.10B |
Volume | 156,684 | 5,229,157 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $133.13 |
52-Week Low | $0.48 | $74.44 |
Typical Hold Time | 16 Days | 67 Days |
Enterprise Value | $3.96M | $22.52B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Lennar (LEN) trades at $77.60, showing modest daily gains amid bearish technical signals. The stock faces fundamental pressure with declining revenue and net income margins, though valuation metrics appear attractive with P/E of 14.42 and P/B below 1. Recent Q3 2026 earnings missed expectations, while Berkshire Hathaway's accumulating stake provides institutional support. Cash flow trends show operational challenges with negative net cash flow in 2025.
Investment outlook balances value opportunity against housing sector headwinds. The stock's below-book valuation and Berkshire's backing offer potential upside, but declining profitability and elevated mortgage rates pose significant risks. Analyst consensus leans cautiously optimistic with 46% buy ratings, though technical indicators suggest near-term bearish pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
